GLI Transcription Factors in Breast Cancer: Malignant‐State Maintenance, Phenotypic Plasticity, and Therapeutic Implications
Journal of Cellular Biochemistry · 2026-11 · 127 (11)
DOI: 10.1002/jcb.70140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Biochemistry, online erschienen am 15.11.2026. Verfasst von Ming-Zhi Lai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Zinc Finger Protein GLI1, Transcription Factors. Die Arbeit nennt 167 Literaturangaben. Gefördert von: Jiangxi Province Science and Technology Innovation Talent Project, Science and technology innovation base plan of Jiangxi Province-Key Laboratory of Jiangxi Province for Transfusion Medicine, General Project of Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
Breast cancer mortality is driven largely by distant metastasis and treatment resistance rather than by the primary tumor alone. The Hedgehog (Hh)/glioma‐associated oncogene (GLI) signaling axis has emerged as an important regulator of these aggressive phenotypes. In this narrative review, informed by a targeted literature search, we synthesize evidence that GLI1, GLI2, and GLI3 have partially divergent and context‐dependent functions. GLI1 is associated with maintenance of proliferative, stem‐like, invasive, and therapy‐tolerant programs, whereas the balance between full‐length and processed GLI2/3 forms contributes to context‐dependent transcriptional outputs. The terms “amplifier” and “switcher” are used as an interpretive framework rather than as experimentally validated temporal categories. Canonical Hh signaling and non‐canonical inputs from TGF‐β/SMAD, Wnt/β‐catenin, NF‐κB, STAT3, hypoxia‐associated signaling, receptor tyrosine kinases, nuclear receptors, and stromal cells converge on GLI regulation. The resulting outputs are linked to epithelial–mesenchymal plasticity, cancer stem‐cell states, metastasis, and therapy resistance. Most therapeutic evidence remains preclinical; therefore, prospective validation and isoform‐resolved biomarkers are required before the proposed framework can guide treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, PR China.
ORCID-Profile: Ming-Zhi Lai, Bo-Xuan Zhou
Förderung
- Jiangxi Province Science and Technology Innovation Talent Project
- Science and technology innovation base plan of Jiangxi Province-Key Laboratory of Jiangxi Province for Transfusion Medicine
- General Project of Jiangxi Provincial Natural Science Foundation
- Jiangxi Province 'Ganpo Talent Program' Innovation Leadership Talent
- Natural Science Foundation of Jiangxi Province
- Science and Technology Plan Project of Jiangxi Provincial Health Commission
- Key Project of Jiangxi Provincial Department of Education
- The First Affiliated Hospital of Nanchang University Young Talent Research Cultivation Fund
Zitieren
APA
Lai, M. Z., Zhu, Z. Y., & Zhou, B. X. (2026). GLI Transcription Factors in Breast Cancer: Malignant‐State Maintenance, Phenotypic Plasticity, and Therapeutic Implications. Journal of Cellular Biochemistry, 127(11). https://doi.org/10.1002/jcb.70140
Vancouver
Lai MZ, Zhu ZY, Zhou BX. GLI Transcription Factors in Breast Cancer: Malignant‐State Maintenance, Phenotypic Plasticity, and Therapeutic Implications. Journal of Cellular Biochemistry. 2026;127(11). doi:10.1002/jcb.70140
BibTeX
@article{Lai2026,
author = {Lai, Ming-Zhi and Zhu, Zheng-Yu and Zhou, Bo-Xuan},
title = {GLI Transcription Factors in Breast Cancer: Malignant‐State Maintenance, Phenotypic Plasticity, and Therapeutic Implications},
journal = {Journal of Cellular Biochemistry},
year = {2026},
volume = {127},
number = {11},
doi = {10.1002/jcb.70140}
}
EUVIMED